Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2021 Filed Nov 22, 2021 23:16 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 956 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000032 · primary_doc.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,595 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2022, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 18, 2021 Filed Jan 4, 2022 22:42 UTC Amendment |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 638 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-000624 · form4a.xml · nonDerivative · entry 3 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,933 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Aug 19, 2022 01:33 UTC |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 956 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021340 · form5.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,823 F1 · date: Administrative error prevented timely filing. F2 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2022, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 22:44 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 42,210 | $254.81 | $10,755,530.10 |
DisclosureSEC source: 0001127602-21-029587 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,010 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 22:38 UTC |
Ghoshal KaushikPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 5,112 | $254.81 | $1,302,588.72 |
DisclosureSEC source: 0001127602-21-029580 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,474 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 22:03 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 12,060 | $254.81 | $3,073,008.60 |
DisclosureSEC source: 0001127602-21-029558 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,412 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 22:01 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 27,135 | $254.81 | $6,914,269.35 |
DisclosureSEC source: 0001127602-21-029557 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,942 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 21:04 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 9,655 | $254.81 | $2,460,190.55 |
DisclosureSEC source: 0001127602-21-029539 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,137 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 16, 2021 Filed Nov 19, 2021 01:13 UTC Amendment |
Leong JustinPresident, Asia Latin America
|
Tax withholdingReMed Common Stock | 765 | $254.81 | $194,929.65 |
DisclosureSEC source: 0001127602-21-029616 · form4a.xml · nonDerivative · entry 2 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,092 F2 · kind: Amended to report the disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018, 11/21/2019 and 11/19/2020. Read SEC document |
| November 16, 2021 Filed Nov 19, 2021 01:13 UTC Amendment |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 9,162 | $254.81 | $2,334,569.22 |
DisclosureSEC source: 0001127602-21-029616 · form4a.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,857 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:44 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 71,262 | $254.81 | $18,158,270.22 |
DisclosureSEC source: 0001127602-21-029587 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,220 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:41 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 20,360 | $254.81 | $5,187,931.60 |
DisclosureSEC source: 0001127602-21-029582 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,193 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:40 UTC |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 9,162 | $254.81 | $2,334,569.22 |
DisclosureSEC source: 0001127602-21-029581 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,857 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:38 UTC |
Ghoshal KaushikPresident, SaaS Business
|
GrantResMed Common Stock | 9,162 | $254.81 | $2,334,569.22 |
DisclosureSEC source: 0001127602-21-029580 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,586 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:03 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 20,360 | $254.81 | $5,187,931.60 |
DisclosureSEC source: 0001127602-21-029558 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,472 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:01 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 45,811 | $254.81 | $11,673,100.91 |
DisclosureSEC source: 0001127602-21-029557 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,077 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:04 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 17,307 | $254.81 | $4,409,996.67 |
DisclosureSEC source: 0001127602-21-029539 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,792 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 16, 2021 Filed Jan 4, 2022 22:42 UTC Amendment |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 9,162 | $254.81 | $2,334,569.22 |
DisclosureSEC source: 0001127602-22-000624 · form4a.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,857 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 01:44 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-21-029234 · form4.xml · derivative · entry 5 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 01:44 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 8,000 | $271.75 | $2,174,000.00 |
DisclosureSEC source: 0001127602-21-029234 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,266 F3 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 01:44 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-21-029234 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 15:41 UTC |
Burt CarolDirector
|
SaleResMed Common Stock | 1,187 | $270.80 | $321,439.60 |
DisclosureSEC source: 0001127602-21-029398 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 01:44 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 945 | $259.47 | $245,199.15 |
DisclosureSEC source: 0001127602-21-029234 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,266 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/19/2020. F2 · balance_after: Includes 62.8289 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:06 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 983 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-21-029097 · form4.xml · derivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,468 Underlying: ResMed Common Stock · 983 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:06 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GiftResMed Common Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029097 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,485 F2 · kind: Gift of shares to The San Diego Foundation, a 501(c)(3) nonprofit organization. Mr. Pendarvis has no beneficial interest, control or dispositive power over the gifted shares. F3 · balance_after: Includes 64.3996 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:06 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 983 | $101.64 | $99,912.12 |
DisclosureSEC source: 0001127602-21-029097 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:06 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,549 | $259.47 | $401,919.03 |
DisclosureSEC source: 0001127602-21-029097 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,502 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/14/2018, 11/21/2019 and 11/19/2020. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:05 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 4,100 | $259.47 | $1,063,827.00 |
DisclosureSEC source: 0001127602-21-029096 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,112 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted for dates 11/14/2018, 11/21/2019 and 11/19/2020. F2 · balance_after: Includes 35.133 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:03 UTC |
FARRELL PETER CDirector
|
Tax withholdingResMed Common Stock | 342 | $259.47 | $88,738.74 |
DisclosureSEC source: 0001127602-21-029094 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,624 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted 11/19/2020. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:04 UTC |
Ghoshal KaushikPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 976 | $259.47 | $253,242.72 |
DisclosureSEC source: 0001127602-21-029095 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,424 F1 · kind: Disposition to issuer for tax withholding on vesting tranches of Restricted Stock Units granted for dates 11/14/2018, 11/21/2019 and 11/19/2021. F2 · balance_after: Includes 29.706 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:03 UTC |
De Witte JanDirector
|
Tax withholdingReMed Common Stock | 104 | $259.47 | $26,984.88 |
DisclosureSEC source: 0001127602-21-029093 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,033 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 18:18 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 8,748 | $259.47 | $2,269,843.56 |
DisclosureSEC source: 0001127602-21-029088 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,958 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted for dates 11/14/2018, 11/21/2019 and 11/19/2020. F2 · balance_after: Includes 94.5633 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 18:17 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-21-028929 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 18:17 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $260.58 | $651,450.00 |
DisclosureSEC source: 0001127602-21-028929 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,833 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 46.9876 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 18:17 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-21-028929 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 15:57 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,485 | $264.29 | $392,470.65 |
DisclosureSEC source: 0001127602-21-028432 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,987 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 00:56 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $264.35 | $634,430.40 |
DisclosureSEC source: 0001127602-21-028014 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,177 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:28 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-21-027245 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:28 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 8,000 | $255.77 | $2,046,160.00 |
DisclosureSEC source: 0001127602-21-027245 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,149 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:28 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-21-027245 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:57 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-21-026987 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:57 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 5,000 | $253.37 | $1,266,850.00 |
DisclosureSEC source: 0001127602-21-026987 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,786 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:57 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-21-026987 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 22:21 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 234 | $246.52 | $57,685.68 |
DisclosureSEC source: 0001127602-21-026983 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,577 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 07/01/2020. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 16:57 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $260.79 | $387,794.73 |
DisclosureSEC source: 0001127602-21-026630 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,472 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 23:28 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $261.33 | $627,183.12 |
DisclosureSEC source: 0001127602-21-026355 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,479 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 19:08 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-21-025396 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 19:08 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 8,000 | $291.83 | $2,334,640.00 |
DisclosureSEC source: 0001127602-21-025396 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,149 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 19:08 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-21-025396 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:17 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-21-025210 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.